| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Atreca Inc (NASDAQ: BCEL)
BCEL Technical Analysis
5
| As on 14th Jun 2024 BCEL STOCK Price closed @ 0.09 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.88 & Strong Sell for SHORT-TERM with Stoploss of 1.47 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BCELSTOCK Price
| Open | 0.10 | Change | Price | % |
| High | 0.10 | 1 Day | 0.00 | 0.00 |
| Low | 0.09 | 1 Week | 0.00 | 0.00 |
| Close | 0.09 | 1 Month | -0.01 | -10.00 |
| Volume | 138641 | 1 Year | -0.71 | -88.75 |
| 52 Week High 1.82 | 52 Week Low 0.06 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| GNLN | 0.02 | -92.00% |
| OMEX | 0.85 | 97.67% |
| NVDA | 106.43 | 3.62% |
| CNEY | 0.14 | 7.69% |
| OPEN | 0.78 | -7.14% |
| LMDX | 0.02 | 0.00% |
| INTC | 21.49 | 4.37% |
| AKTS | 0.04 | 0.00% |
| TSLA | 259.51 | 3.50% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| BCEL Daily Charts |
BCEL Intraday Charts |
Whats New @ Bazaartrend |
BCEL Free Analysis |
|
|
BCEL Important Levels Intraday
| RESISTANCE | 0.11 |
| RESISTANCE | 0.10 |
| RESISTANCE | 0.10 |
| RESISTANCE | 0.10 |
| SUPPORT | 0.08 |
| SUPPORT | 0.08 |
| SUPPORT | 0.08 |
| SUPPORT | 0.07 |
BCEL Forecast April 2025
| 4th UP Forecast | 1.34 |
| 3rd UP Forecast | 0.94 |
| 2nd UP Forecast | 0.69 |
| 1st UP Forecast | 0.44 |
| 1st DOWN Forecast | -0.26 |
| 2nd DOWN Forecast | -0.51 |
| 3rd DOWN Forecast | -0.76 |
| 4th DOWN Forecast | -1.16 |
BCEL Weekly Forecast
| 4th UP Forecast | 1.59 |
| 3rd UP Forecast | 1.11 |
| 2nd UP Forecast | 0.81 |
| 1st UP Forecast | 0.52 |
| 1st DOWN Forecast | -0.34 |
| 2nd DOWN Forecast | -0.63 |
| 3rd DOWN Forecast | -0.93 |
| 4th DOWN Forecast | -1.41 |
BCEL Forecast2025
| 4th UP Forecast | 3.94 |
| 3rd UP Forecast | 2.71 |
| 2nd UP Forecast | 1.94 |
| 1st UP Forecast | 1.18 |
| 1st DOWN Forecast | -1 |
| 2nd DOWN Forecast | -1.76 |
| 3rd DOWN Forecast | -2.53 |
| 4th DOWN Forecast | -3.76 |
Atreca Inc ( NASDAQ USA Symbol : BCEL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BCEL Business Profile
Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology. Atreca, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Address: 450 East Jamie Court, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service